Glucocorticoid receptor complex with Nuclear factor kappa-light-chain-enhancer of activated B cells and Activator protein 1 (GR-NF-κB-AP-1)

The Glucocorticoid receptor (GR) complex with Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and Activator protein 1 (AP-1) is a pivotal molecular assembly that mediates the potent anti-inflammatory effects of glucocorticoid drugs. Upon activation by a ligand, the GR translocates into the nucleus and physically interacts with the pro-inflammatory transcription factors NF-κB and AP-1 through a process called transrepression (PubMed: 15630443). This interaction prevents these factors from recruiting the necessary coactivators for the transcription of inflammatory cytokines, such as IL-1, IL-6, and TNF-α (PubMed: 10866677). This mechanism is distinct from transactivation, where GR binds directly to glucocorticoid response elements (GREs) on DNA, a process often associated with metabolic side effects (UniProt: P04150). Consequently, this complex is a primary target for treating chronic inflammatory conditions like asthma and rheumatoid arthritis. Current pharmacological research focuses on developing selective glucocorticoid receptor modulators (SEGRMs) that specifically promote transrepression while minimizing transactivation to improve the safety profile of steroid therapies (StatPearls: NBK531462).

Other names

Glucocorticoid receptor-NF-kappaB-AP-1 complexGR-NF-κB-AP-1 complexTransrepression complexGlucocorticoid receptor-tethered transcription factor complex

The complex functions through transrepression, where the ligand-activated glucocorticoid receptor tethers to DNA-bound NF-κB or AP-1, inhibiting their ability to recruit coactivators and initiate transcription of pro-inflammatory genes (PubMed: 15630443).